Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 891 participants.

Also called NCT01785875

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 891 participants (enrolled count) (from the registry)
Sponsor
  • Amgen Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01785875
  • EudraCT 2012-002808-41
Other papers using this trial's data
  • One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2020-10-01 DOI, PubMed 30859218, PMC7538239 PubMed links an erratum for this paper. Erratum: PMID 31093680 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Austria, Belgium, Canada, Czechia, France, Germany, Hungary, Israel, Italy, Netherlands, Poland, Russia, Spain, Sweden, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01785875. Allocation not applicable; no masking; primary purpose treatment. Start 2013-07-31 (actual); primary completion 2015-07-01 (actual). Results posted on 2017-03-27.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis
Condition
Hyperparathyroidism, Secondary
Intervention (Drug)
Etelcalcetide
Lead sponsor
Amgen (class: industry)

Record details

Record id
cardio:ct-nct01785875
Content hash
6a2951e1f911483f6da15cb42913de618d9ca7fb7276dfcb568281caed8dc218